NR4A3 and extraskeletal myxoid chondrosarcoma: Future treatment strategies for EMC would ideally consist of targeting the pathognomonic fusion transcription factor or the downstream effectors of the translocation partner NR4A3, a member of the steroid-thyroid hormone-retinoid receptor superfamily that activates peroxisome proliferator-activated receptor-gamma (PPAR-gamma).